A new batch of drugs has hit the market with 25 billion insulin glycema

For newly approved drugs, it is only when the provinces are online that the product truly enters the sales phase.
, many widely watched varieties officially entered the hospital for sale, meaning that the product pattern of the variety, began to be stirred.
batch of new drugs, listed on January 20, Shaanxi Province Public Resources Trading Center issued a notice to announce the December 2020 declaration of new approved listed drugs and listed on the Internet to apply for price adjustment of new approved drugs information.
According to the publicity form, the newly approved drugs are pyrithione chloride tablets (I), amphetamine hydrochloride slow-release tablets, metformin hydrochloric acid slow-release tablets (II), propofol/long-chain fat emulsions, Pribarin capsules, mendon insulin 30 injections, hydrochloric acid ensarini capsules and other 22, involving a total of 15 well-known pharmaceutical companies, including Liaoning Haisco Pharmaceutical Co., Ltd., Yichang People's Fu Pharmaceutical Co., Ltd., Zhengda Tianqing Pharmaceutical Group Co., Ltd., China Resources Shuanghe Pharmaceutical Co., Ltd., Beda Pharmaceutical Co., Ltd.
, the newly approved drugs are not short of highly competitive varieties, and this time there is a new generic drug market, will impact its market.
25 billion insulin, glycerine launched a shock last November, Ganli Pharmaceuticals' mendong insulin 30 injection into the administrative approval stage, Tonghua Dongbao's 2.1 class of new drug super-speed effect of insulin injection was also approved clinically.
time, seven insulin products were on the market for retrial.
, mendong insulin injections are the most declared and accepted, involving Zhejiang Haizheng Pharmaceuticals, Tonghua Dongbao, Zhuhai Federal Pharmaceuticals.
According to Minenet data, in recent years, China's public medical institutions end-door winter insulin injection sales of more than 6 billion yuan, in the first half of 2020, an increase of 16.30% year-on-year, the production enterprises only No.
In fact, earlier in the domestic market, men's winter insulin was dominated by Noor and Nord, involving products including men's winter insulin 30 injections, men's winter insulin injections and men's winter insulin 50 injections, glycero pharmaceutical industry in May 2020 after winning the first men's winter insulin injections in the country, and again in December took the men's winter insulin 30 injections in the country's first.
As far as insulin is a big category, Milnet data show that in recent years, China's public medical institutions end chemical insulin and similar drug sales of more than 20 billion yuan, in 2019 a new high, sales of nearly 25 billion yuan;
in the insulin market, multinational pharmaceutical companies still occupy a leading position, No. 1 and Nord, Sanofi, Lilly three combined market of more than 70%.
It is worth noting that mendon insulin 30 injections listed glycelin pharmaceutical industry, its products recombinant insulin glycerin injections in 2020 chemical insulin and similar drug brand TOP20 ranked fourth, sales growth rate of 21.5%, market share of 9.33%.
At present, Glycerides pharmaceutical industry has long-acting insulin glycerin, quick-acting insulin, mendon insulin and refined protein zinc recombinant insulin mixture injection (25R) four recombinant insulin-like items, the whole product line of insulin layout, has become the main force in the insulin market.
varieties, the official hanging net this time in Shaanxi Province hanging net new products, many are familiar with the industry's large varieties.
, the world's first ARB/CCB single-piece compound preparation for the treatment of primary hypertension.
The python tan ammonia chloride flat tablets (I.) are 80 mg per tablet containing pyridha tan, 5 mg of ammonia chloride flat tablets (II.) each piece containing 160mg of python tan and 5 mg of ammonia chlorine flat, all produced by Novaral.
was approved for listing in the European Union and the United States in 2007, with global sales of $1.002 billion in 2018.
entered the Chinese market at the end of 2009, the combined sales of the Pyurora Tan ammonia chloride tablets (I.) in China's public medical institutions and retail pharmacies terminals in Chinese cities in 2017 amounted to 1,383 million yuan.
and Garden Pharmaceuticals at the same time applied for the listing of four classes of generic drugs three other pharmaceutical companies, namely Kun Pharmaceutical Group, Beijing Baiao Pharmaceuticals, Hengrui Pharmaceuticals.
to declare the drug market according to the new registration classification of chemicals, after being approved for listing, it is regarded as passing a consistent evaluation, whether it is regional or national collection, there is? Over-reviewed? label, opening up the market resistance will be less.
addition, cyclophenol injection as a newly approved product, also officially hung in Shaanxi network.
December 14, the State Drug Administration announced that it had approved the listing of a class 1 innovative drug cyclophenol injection (commodity name: Sisshuning) declared by Liaoning Hai Cisco Pharmaceutical Co., Ltd. through a priority review and approval process.
the drug is also An innovative drug with independent research and intellectual property rights in China, which is used for sedative sedative examination in the digestive tract endoscopy.
cyclophenols are GABAA-like astrologists, anaesthetic sedatives.
data show that cyclophenol (the commodity name is Sisshuning) is an innovative class 1.1 drug developed by Hesco with full independent intellectual property rights, and is also the first intravenous anesthetic drug in China to innovate its own compounds.
the drug is an improved new drug of the classic anaesthetic sedative propofol, which is significantly more effective than propofol and is more safe than propofol. according to the
insight database, domestic sales of propofol emulsions and propofol medium/long-chain fat emulsions in 2019 were RMB3.672 billion and RMB 1.95 billion, respectively, of which the market for propofol medium/long-chain fat emulsions was mainly occupied by Fessenyuskabi.
the Haisco Pharmaceuticals 1 class of new drugs officially listed, will eat up how much propofol market? Cypress Blue will keep a close eye on it.
, for newly approved drugs, it is only when the provinces are online that the product really enters the sales phase.
, many widely watched varieties officially entered the hospital for sale, meaning that the product pattern of the variety, began to be stirred.